MATERIALS AND METHODS
6D1 (provided by Dr Barry S. Coller, SUNY, Stony Brook, NY) is a murine IgG monoclonal antibody (MoAb) directed at the vWf binding site on the glycocalicin portion of the a-chain of GP1b.I.' WM23 and AK3 (provided by Dr Michael C. Berndt, University of Sydney, Australia) are both murine IgG MoAbs directed at the macroglycopeptide portion of glycocalicin, rather than the N-terminal protein portion that contains the vWF and 6D1 binding S12 (provided by Dr Rodger P. McEver, University of Oklahoma) is a murine IgG MoAb directed against GMP-140.I8 GMP-140, also referred to as platelet activationdependent granule-external membrane (PADGEM) protein," is a component of the a-granule membrane of resting platelets that is expressed on the platelet plasma membrane only after platelet activation and secretion."
Incubation of plasmin-treated platelets in autologous plasma. Peripheral venous blood obtained from healthy volunteers was drawn into a syringe containing one-seventh volume of acid-citrate-dextrose (trisodium citrate 85 mmol/L, citric acid 71 mmol/L, dextrose 11 1 mmol/L, pH 4.5) resulting in a final pH of 6.5, as previously described.20 Platelet-rich plasma (PRP) was then prepared as previously described.'" Autologous plasma was prepared by centrifugation of the remaining blood (2,000 g, 10 minutes, 22OC), removal of the upper two-thirds of the supernatant, and adjustment of the pH
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platelet GPlb content (measured by enzyme-linked immunosorbent assay [ELISA], sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and flow cytometry) remained reduced, quantitatively corresponding to an increase in plasma glycocalicin concentration (measured by ELISA). The loss and restoration of platelet surface GPlb occurred on all platelets and, as evidenced by lack of inhibition by prostaglandin E,. EDTA, and cytochalasins, was not mediated by cyclic AMP, extracellular ca'*, or the platelet microfilament system. In summary, this study shows that after plasmin-mediated cleavage of platelet surface GPlb. platelets can replenish their surface GPlb pool by recruitment of GPlb molecules from the intraplatelet pool (or from a sequestered surface site). 0 1990 by The American Society of Hematology.
to 7.2 with 1 mol/L NaOH. A suspension of platelets was obtained from the PRP by washing it twice in modified Tyrode's buffer [138 mmol/L NaCI, 2.9 mmol/L KCI, 12 mmol/L NaHCO,, 0.4 mmol/L NaHPO,, 0.1% glucose, 0.35% bovine serum albumin (BSA), pH 6.51 with 50 ng/mL prostaglandin E, (PGE,), as previously described.'" The final resuspension of platelets was in modified Tyrode's buffer, pH 7.3, with 50 ng/mL PGE, and 1 mmol/L EDTA. In other experiments, the final resuspension of platelets was in modified Tyrode's buffer, pH 7.3, with 1 mmol/L CaCI,. The platelets (5 x 10s/pL) were then incubated (1 hour, 22OC) with various concentrations of freshly reconstituted plasmin (KABI through Helena Laboratories, Beaumont, TX). Control samples were incubated without plasmin. Plasmin digestion was inhibited by adding to all samples an equal volume of autologous plasma; the samples were incubated for 3 hours at 37OC. In some experiments, one of the following was included in the 3-hour incubation: (a) 6 pmol/L cytochalasin B (Sigma, St Louis, MO) in 0.4% dimethyl sulfoxide (DMSO) (Sigma), (b) 0.75 pmol/L cytochalasin D (Sigma) in 0.4% DMSO, (c) 0.4% DMSO, or (d) buffer only. At various time points, aliquots were withdrawn and were either (a) fixed with 1% formaldehyde as previously described" and assayed by flow cytometry for either platelet surface GPIb or whole platelet GPIb content; (b) assayed for whole platelet GPIb content by either enzyme-linked immunosorbent assay (ELISA) or sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE); (c) analyzed for ristocetin-induced platelet agglutination; or (d) centrifuged (8,000 g, 10 minutes, 22OC), after which the upper The ELISA method has been described previously?*' A monolayer of platelets was fixed to plastic microwells, and the ability of diluted plasma samples to inhibit the binding of monoclonal antibody 6D1 to platelet surface GPIb was compared with a standard curve of the inhibition of 6D1 binding by known nanomolar concentrations of purified glycocalicin. All assays were performed in triplicate. We previously demonstrated' that centrifugation of plasma at 22OC for 2 hours at 100,000 g (ie, at forces in excess of those required to sediment platelets and microparticles") results in no change in the glycocalicin content of the supernatant, as determined by ELISA. Thus, the ELISA measures only soluble glycocalicin, not microparticle-associated glycocalicin or GPIb.
Ristocetin-induced platelet agglutination. Platelets (250,000/ pL) suspended in autologous plasma were stirred with 1.2 mg/mL ristocetin (BioData, Horsham, PA) in a Lumi-Aggregation Module series 10008 (Payton, Buffalo, NY). Platelet agglutination was detected by change in light transmission, as previously de~cribed.'~ The flow cytometry method has been described previou~ly.~~'"~~ Formaldehydefixed platelets were washed, incubated with a saturating concentra- Whole platelet GPIb content determined by flow cytometry. Formaldehyde-fixed platelets (25,00O/pL) were incubated (30 minutes, 22OC) with FITC-labeled MoAb 6Dl (in sevenfold excess of the saturating concentration for platelet surface GPIb) or FITClabeled mouse IgG (Jackson ImmunoResearch, West Grove, PA) and 0.1% Triton X-100 (Sigma) in phosphate-buffered saline (PBS, 137 mmol/L NaCl, 2.7 mmol/L KCl, 1.5 mmol/L KH2P04, 8.1 mmol/L NazHP04, pH 7.4) with 0.35% BSA and then diluted 10-fold in PBS with 0.35% BSA. Nonpermeabilized controls were prepared identically except that Triton X-100 was omitted. The samples were analyzed in an EPICS Profile flow cytometer. For each sample, the fluorescence signal from 10,000 individual cells was measured. Background binding obtained from parallel assays with the mouse IgG was subtracted from each sample. The fluorescence intensity of 1% formaldehyde-fixed platelets was 26.5% f 1.8% (mean f SEM, n = 3) lower than unfixed samples, demonstrating that formaldehyde fixation did not permeabilize the platelets. During graded Serratia protease cleavage of platelet surface GPIb?* the mean fluorescence intensity of fixed platelets plotted as a function of the fluorescence intensity of equivalent unfixed samples generated a straight line that passed through the origin, thereby demonstrating that fixation did not interfere with quantitation in this assay. Treatment of 6DI-labeled, washed, nonpermeabilized platelets with 0.1% Triton X-100 for 30 minutes at 22OC did not diminish the fluorescence signal as compared with platelets not treated with Triton, demonstrating that 0.1% Triton X-100 treatment of fixed platelets did not result in extraction of the 6D1 epitope. As determined by flow cytometry, the whole platelet GPIb content was 286.0% * 9.4% (mean + SEM, n = 3) of the platelet surface GPIb pool. That the whole platelet GPIb content was less by this intact platelet method than as determined from solubilized platelets by ELISA and SDS-PAGE methods' probably reflects one or more of the followingz3: decreased accessibility of intracellular antigen because of cross-linking of surrounding protein matrix, a different Plasma glycocalicin determined by ELISA.
Platelet surface GPIb determined by flow cytometry.
fixation-induced loss of immunoreactivity for intracellular and platelet surface antigen, or self-quenching of fluorescence owing to close packing of intracellular antigen.
Wholeplatelet GPIb content determined by ELISA. The ELISA method has been described previously.' The platelets were washed in modified Tyrode's buffer and lysed by addition of an equal volume of buffer containing 2% Triton X-100 (Sigma), 100 mmol/L Tris-HC1, pH 7.4, with 2 mg/mL leupeptin (Sigma). The samples were then centrifuged at 8,000 g for 4 minutes, conditions that do not sediment most of the actin fiiament-associated GPIb.7,24 The resulting supernatants were assessed by ELISA (as described above) for their ability to inhibit MoAb 6D1 binding to platelet surface GPIb. Each platelet lysate was assayed at two dilutions, three times each.
The SDS-PAGE method has been described previously.' Washed whole platelets were subjected to SDS-PAGE (with 5% polyacrylamide), stained with periodic acid-Schiffs reagent, and analyzed by a video image processing system with Imagemeasure (Microscience, Federal Way, WA), and the amount of GPIb was calculated.'
Thrombin-induced downregulation of platelet surface GPIb determined byflow cytometry. The flow cytometry method, which used purified human a-thrombin (provided by Dr John Fenton 11, New York Department of Health, Albany, NY), has been described previously.'O Whole platelet GPIb content determined by SDS-PAGE.
RESULTS
We wished to determine whether platelets can replenish the surface G P I b pool after plasmin-mediated cleavage of platelet surface GPIb. First, we incubated washed platelets with plasmin for 1 hour at 22OC. Increasing concentrations of plasmin resulted in decreasing degrees of ristocetin-induced platelet agglutination, as determined by a standard nephelometric technique (Fig 1,0 time point) . Plasmin digestion was then inhibited by addition of an equal volume of autologous plasma, and the samples were incubated for 3 more hours at 37OC. This incubation resulted in a gradual recovery of ristocetin-induced platelet agglutination (Fig 1) .
To confirm that this effect was the result of a change in platelet surface GPIb, aliquots of the same samples were assessed by flow cytometry using two GPIb-specific MoAbs (WM23 and 6DI). Incubation with plasmin resulted in a decrease in the platelet surface expression of G P I b that paralleled the decrease in ristocetin-induced platelet agglutination (Fig 2) . The subsequent incubation in autologous plasma resulted in a gradual restoration of the platelet surface expression of GPIb, the kinetics of which paralleled the return of ristocetin-induced platelet agglutination (Fig   2) .
Performance of these experiments without PGE, and with 1 mmol/L CaCl, rather than 1 mmol/L EDTA, resulted in a similar restoration of platelet surface G P I b expression, as determined by both ristocetin-induced platelet agglutination and flow cytometry with antibodies W M 2 3 and 6D1 (data not shown).
The ability of the flow cytometric technique to analyze individual platelets" enabled us to determine that the loss and restoration of platelet surface G P I b expression was not confined to a subpopulation of platelets but occurred to a similar extent on all platelets (Fig 3) .
To determine whether GPIb molecules were redistributed between the intraplatelet and plasma pools, aliquots of the same samples were analyzed by E L I S A for whole platelet GPIb content and for glycocalicin released into the plasma medium (Table 1) . Although 3 hours of incubation of plasmin-treated platelets in autologous plasma resulted in restoration of platelet surface GPIb (Figs 1 through 3) , the whole platelet GPIb content was reduced in proportion with the observed increase in the glycocalicin concentration of the plasma medium (Table 1 ). There were no significant changes in platelet counts during these experiments. SDS-PAGE and flow cytometric analysis of permeabilized platelets were used to verify by independent methods that incubation of plasmin-treated platelets in autologous plasma can result in a redistribution of GPIb molecules between intraplatelet and platelet surface pools. During a 1-hour incubation, plasmin 0.125 CU/mL resulted in a loss of platelet surface GPIb (Fig 4A) and a reduction in whole platelet GPIb content (Fig 4B) . The loss of whole platelet GPIb content with plasmin 0.125 CU/mL was approximately 50%, whether the whole platelet GPIb content was measured by flow cytometric analysis of permeabilized platelets (Fig 4B) , SDS-PAGE (Fig 4B) , or ELISA ( Table  1) . As determined by flow cytometry, the decrease in the whole platelet GPIb content was not confined to a subpopulation of platelets but occurred to a similar extent on all platelets (data not shown). After a 3-hour incubation in autologous plasma, there was some replenishment of the platelet surface GPIb pool (Fig 4A) but no change in the whole platelet GPIb content, as determined by both SDS-PAGE and flow cytometry (Fig 4B) . There were no significant changes in platelet counts during these experiments.
To determine whether the platelet microfilament system Washed platelets were incubated with plasmin or buffer for 1 hour at 22'C and then with an equal volume of autologous plasma for 3 hours at 37OC.
Whole platelet GPlb content and plasma glycocalicin were then determined by ELSA using MoAb 6D 1. These data were obtained from the same experiments shown in Figs. 1 through 3 . Mean f SEM, n = 3 separate experiments. *Plasmin-mediated release of glycocalicin into plasma medium was calculated by subtraction of the glycocalicin content of the medium of the non-plasmin-treated platelet sample: 22.4 f 6.2 nmol/L, or 54,000 f 8.000 molecules per platelet (of which 50,000 f 9,000 molecules per platelet derived from plasma and 4,000 f 3,000 molecules per platelet was shed from platelets).
had a role in the plasmin-induced redistribution of GPIb molecules, experiments were performed in which cytochalasins (inhibitors of actin polymerizationz5) were added to the autologous plasma incubation. As shown in Fig 4A and B, 6 pmol/L cytochalasin B had no effect on redistribution of GPIb to the surface. In parallel samples, 6 pmol/L cytochalasin B did affect human a-thrombin-induced downregulation of platelet surface GPIb expression. In the presence of DMSO only, thrombin 1.0 U/mL induced reductions of 95.3% and 92.4% in the platelet surface binding of antibodies 6D1 and AK3, respectively. With DMSO and cytochalasin B added, thrombin 1.0 U/mL induced reductions of only 27.5% and 22.7% in the binding of 6D1 and AK3, respectively. In both the plasmin and thrombin experiments, 0.75 pmol/L cytochalasin D produced results similar to those of cytochalasin B (data not shown). Because high concentrations of plasmin can induce platelet activationz6 and platelet activation can result in decreased platelet surface GPIb expression,'-" experiments were performed to determine whether plasmin was inducing platelet activation under the present experimental conditions (Fig 5) . That the plasmin-induced loss of platelet surface expression of GPIb was not the result of platelet activation was confirmed because at the concentrations of plasmin used in this study (50.125 CU/mL) the decrease in platelet surface binding of the GPIb-specific MoAb 6D1 was not associated with an increase in platelet surface binding of the GMP-140-specific MoAb S12 (Fig 5) . In contrast, thrombin-induced downregulation of platelet surface GPIb was associated with platelet activation, as evidenced by GMP-140 surface exposure (Fig 5) .
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DISCUSSION
This study showed that after proteolytic cleavage of platelet surface GPIb by plasmin, platelets can replenish their surface GPIb pool by recruiting GPIb molecules from an intraplatelet pool (or from a sequestered surface site). The replenishment of platelet surface GPIb was demonstrated by both an immunological method (flow cytometry with MoAbs) and a functional method (ristocetin agglutination). The ability of the flow cytometric method to analyze individual platelets" enabled us to demonstrate that all platelets are able to upregulate platelet surface GPIb. That there was a redistribution of GPIb between the intraplatelet, platelet surface, and plasma (glycocalicin) pools was demonstrated by a reduction in whole platelet GPIb content (independently determined by ELISA, SDS-PAGE, and flow cytometry) in proportion with an increase in plasma glycocalicin concentration. Thus, the upregulation of platelet surface GPIb did not result from synthesis of new protein or uptake of plasma glycocalicin.
Together with previous studies,7.'-" this study showed that GPIb molecules can traffic between intraplatelet and platelet surface pools. We recently demonstrated that in vitro platelet storage results in a redistribution of GPIb molecules in the direction of intraplatelet to platelet surface pools? In contrast, welo and other investigators'." showed that thrombin induces a downregulation of platelet surface GPIb that is the The upregulation of platelet surface GPIb was independent of (a) platelet activation (because, in contrast to the present findings, platelet activation results in downregulation of platelet surface GPIb, unchanged whole platelet GPIb content, and no release of glyco~alicin~'"), (b) extracellular Ca2+ (as evidenced by the lack of inhibition by EDTA), and (c) cyclic AMP (as evidenced by the lack of inhibition by PGE,).
Possible control mechanisms for the upregulation of platelet surface GPIb include a transmembrane signalling event, a pH gradient through successive membrane compartments, and GTP-binding proteins.28 At the concentrations of plasmin used (0.03125 to 0.125 CU/mL), the plasmin-mediated cleavage of the N-terminal protein portion of the a-chain of GPIb (reported by MoAb 6D1) was greater than the plasmin-mediated cleavage of the macroglycopeptide portionz9 of the a-chain of GPIb (reported by MoAbs WM23 and AK3) (Figs 2 and 4) , consistent with the fact that the a-chain of GPIb contains several cleavage sites for ~1asmin.I~ The subsequent upregulation of platelet surface GPIb was complete as determined by WM23 and AK3 but incomplete as determined by 6D1 (Figs 2 and 4) , raising the possibility that cleavage of (part of) the macroglycopeptide portion of the a-chain of GPIb is necessary, and that cleavage of the N-terminal protein portion of the a-chain of GPIb is insufficient, to initiate the signal for upregulation of platelet surface GPIb. There are precedents for redistributions of GP receptor molecules between intraplatelet and platelet surface membrane pools. The GPIIb-IIIa complex (a receptor for fibrinogen, vWF, fibronectin, and vitronectin3') redistributes from an intraplatelet pool to the platelet surface pool in response to thrombin activation."-33 Evidence has been presented for active cycling of GPIIb-IIIa between intraplatelet and platelet surface GMP-140 (also known as PADGEM protein), a receptor that mediates the interaction of activated platelets with neutrophils and monocyte^,^^.^^ is translocated from an intraplatelet a-granule membrane pool to the platelet plasma membrane on platelet a~tivation.'~.~'
Carefully performed in vivo studies will be necessary to determine whether the presently described plasmin-induced redistribution of platelet GPIb molecules can occur during clinical fibrinolytic states, eg, infusion of thrombolytic agents or disseminated intravascular coagulation.
